All News

It's isolating to have cancer. Making a connection with someone who understands makes all the difference.

Richard Finn, of the Jonsson Comprehensive Cancer Center at UCLA and lead investigator of the PALOMA-1 study, explains the clinical implications of Ibrance's approval for hormone-positive, HER2-negative metastatic breast cancer.

With a deadline of April 14, the FDA will soon make its final approval decision on lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).

Ixazomib, also known as MLN9708, met its primary endpoint of improving progression-free survival at an interim analysis of a phase 3 trial of relapsed or refractory multiple myeloma.

The Multiple Myeloma Research Foundation provides educational programs to help people with myeloma, family members, caregivers, and healthcare professionals learn more about the disease and today's most promising treatment options, including clinical trials, from leading multiple myeloma doctors and researchers.

At least 10 vaccine candidates have entered advanced testing phases on the strength of impressive early stage results.

Medicare will immediately cover lung cancer screening with low-dose computed tomography (LDCT) for high-risk individuals, including current and former smokers, according to a national coverage determination (NCD) released by CMS.

We have all heard that personalized medicine holds great promise for cancer treatment, but what does it really mean?

My goal is to educate doctors around the globe about helping to diagnose Lynch syndrome and to continue to help patients who need support.

Thanks to The Cancer Genome Atlas (TCGA) Research Network, researchers now have a better understanding of genomic alternations in head and neck cancers.

Issues of fertility, body image and sexuality are all important when treating a young adult with cancer, yet many facilities lack proper utilities and training to assist this group of patients, which is why Anne Katz wrote the book, "This Should Not Be Happening: Young Adults with Cancer."

On the evolving role of PARP inhibitors in the treatment of ovarian cancer, Donna McNamara, co-chief of Gynecological Oncology at the John Theurer Cancer Center (JTCC), discusses the impact of these studies and the outlook going forward.

There's a list of things we're supposed to do as good patients. And then, there's the reality of living with cancer and doing the best we can.

Women diagnosed with early-stage breast cancer have a variety of decisions to make regarding treatment, but it's important for patients to realize all of their options when making those medical decisions.

In which Kevin introduces himself, catches the world up to date on his cancer battle, and sprinkles in some random bits of wisdom

A phase 3 study of Gazyva in indolent non-Hodgkin lymphoma has been stopped early after an interim analysis found the drug improved progression-free survival.

Michelle Gervino, an oncology nurse with John Theurer Cancer Center, advises patients to communicate with their medical team about any side effects they may be experiencing.

Each year on Feb. 4, people from around the world recognize World Cancer Day, an initiative to increase awareness of the global burden of cancer and promote strategies for reducing cancer incidence and death rates.

The anticipated approval of Ibrance (palbociclib) came two months ahead of expectations, as the FDA granted an accelerated approval to the drug as a frontline treatment for women with ER-positive, HER2-negative metastatic breast cancer.

Carl Harrington, president of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), explains the importance of Imbruvica's approval for the rare disease.

The Food and Drug Administration (FDA) granted a priority review to Yondelis to treat patients with the disease, including liposarcoma and leiomyosarcoma subtypes, who have previously received chemotherapy that included an anthracycline. The FDA will make its final approval decision within six months.

Knowing how genes and nutrients interact could likewise be the prescription for improved health.

Cancer moves fast; we need to move faster. Help make sure patients have access to important diagnostic tests.

The PD-L1 inhibitor MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer (NSCLC) that has progressed on prior therapy.

The FDA's framework for regulating lab developed tests could keep some patients from receiving validated diagnostic tests and targeted treatments like mine.

During President Barack Obama's State of the Union Address, he announced a nationwide Precision Medicine Initiative that would help cure diseases such as cancer and diabetes.

A new study has found that while the breast cancer prevention drug tamoxifen's benefits outweigh its risks, the drug isn't right for all women.

Ibrutinib becomes the first drug specifically approved for Waldenstrom's macroglobulinemia (WM), two months ahead of expectations.

Every day, breast cancer researcher Edith Perez sets her mind on finding better treatments for the disease and conducting research aimed at improving patients' lives.

When motivating people to get screened for cancer, fear may not be the best way to do it.